14 May 2021
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 1,632,798 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 462,798 options to Chief Executive Officer, Dr Jon Burrows, 480,000 options to Chief Financial Officer, Paul Stockdale and 150,000 options to Chief Operating Officer, Thomas Guiel, who is a person discharging managerial responsibility. The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of £1 per share.
One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
Following this grant, Dr Jon Burrows, Paul Stockdale and Thomas Guiel hold options over Ordinary Shares and are interested in Ordinary Shares as follows:
| | Total number of options over Ordinary Shares | Ordinary Shares held | |
| Number | % of current issued share capital | ||
| Jon Burrows | 1,388,396 | Nil | - |
| Paul Stockdale | 600,000 | 15,000 | 0.02 |
| Thomas Guiel | 150,000 | Nil | - |
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Jon Burrows |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 462,798 ordinary shares at an exercise price of 100 pence per share
|
| d) | Aggregated information - Aggregated volume - Price
| N/A
|
| e) | Date of the transaction | 14 May 2021
|
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Paul Stockdale |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 480,000 ordinary shares at an exercise price of 100 pence per share
|
| d) | Aggregated information - Aggregated volume - Price
| N/A
|
| e) | Date of the transaction | 14 May 2021
|
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Thomas Guiel |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 150,000 ordinary shares at an exercise price of 100 pence per share
|
| d) | Aggregated information - Aggregated volume - Price
| N/A
|
| e) | Date of the transaction | 14 May 2021
|
| f) | Place of the transaction | Outside a trading venue |
-Ends-
For further details please contact:
| Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
| Tel: +44 (0)1865 518910 |
| Shore Capital - Nominated Adviser and Broker Advisory: Edward Mansfield / John More Broking: Fiona Conroy
| Tel: +44 (0)20 7408 4090 |
| Instinctif Partners Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Nathan Billis | Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
Oxford BioDynamics is leveraging its technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, neurodegenerative and autoimmune diseases, to follow its commercial EpiSwitch® CST (Covid Severity Test).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
